These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1619397)

  • 21. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
    Zapata JC; Goicochea M; Nadai Y; Eyzaguirre LM; Carr JK; Tallon LJ; Sadzewicz L; Myers G; Fraser CM; Su Q; Djavani M; Lukashevich IS; Salvato MS
    J Virol; 2014 Mar; 88(6):3058-66. PubMed ID: 24335292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostics for Lassa Fever: Detecting Host Antibody Responses.
    Salvato MS; Lukashevich IS; Medina-Moreno S; Zapata JC
    Methods Mol Biol; 2018; 1604():79-88. PubMed ID: 28986826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV vaccines from IV cell-free or cell-associated homologous challenge.
    Osterhaus A; de Vries P; Morein B; Akerblom L; Heeney J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1507-10. PubMed ID: 1466991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.
    Lukashevich IS; Patterson J; Carrion R; Moshkoff D; Ticer A; Zapata J; Brasky K; Geiger R; Hubbard GB; Bryant J; Salvato MS
    J Virol; 2005 Nov; 79(22):13934-42. PubMed ID: 16254329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.
    Cross RW; Xu R; Matassov D; Hamm S; Latham TE; Gerardi CS; Nowak RM; Geisbert JB; Ota-Setlik A; Agans KN; Luckay A; Witko SE; Soukieh L; Deer DJ; Mire CE; Feldmann H; Happi C; Fenton KA; Eldridge JH; Geisbert TW
    J Clin Invest; 2020 Jan; 130(1):539-551. PubMed ID: 31820871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC; Lloyd G
    Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical virology of Lassa fever in hospitalized patients.
    Johnson KM; McCormick JB; Webb PA; Smith ES; Elliott LH; King IJ
    J Infect Dis; 1987 Mar; 155(3):456-64. PubMed ID: 3805773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.
    Carlson JR; McGraw TP; Keddie E; Yee JL; Rosenthal A; Langlois AJ; Dickover R; Donovan R; Luciw PA; Jennings MB
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1239-46. PubMed ID: 2078406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains.
    Mateo M; Reynard S; Journeaux A; Germain C; Hortion J; Carnec X; Picard C; Baillet N; Borges-Cardoso V; Merabet O; Vallve A; Barron S; Jourjon O; Lacroix O; Duthey A; Dirheimer M; Jouvion G; Moreau PH; Fellmann L; Carbonnelle C; Raoul H; Tangy F; Baize S
    Sci Transl Med; 2021 Jun; 13(597):. PubMed ID: 34108251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.
    Jahrling PB
    J Med Virol; 1983; 12(2):93-102. PubMed ID: 6619814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
    Carrion R; Patterson JL; Johnson C; Gonzales M; Moreira CR; Ticer A; Brasky K; Hubbard GB; Moshkoff D; Zapata J; Salvato MS; Lukashevich IS
    Vaccine; 2007 May; 25(20):4093-102. PubMed ID: 17360080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development and study of properties of immunoglobulins against Lassa fever].
    Krasnianskiĭ VP; Gradoboev VN; Borisevich IV; Potryvaeva NV; Lebedinskaia EV; Chernikova NK; Timan'kova GD
    Vopr Virusol; 1997; 42(4):168-71. PubMed ID: 9304297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunogenic and protective characteristics of recombinant Lassa virus NP protein].
    Ignat'ev GM
    Vopr Virusol; 2002; 47(2):28-31. PubMed ID: 12046464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever].
    Firsova IV; Shatokhina IV; Borisevich IV; Evseev AA; Maksimov VA; Pantiukhov VB; Khmelev AL
    Vopr Virusol; 2003; 48(6):43-5. PubMed ID: 14708232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.
    Jahrling PB; Hesse RA; Eddy GA; Johnson KM; Callis RT; Stephen EL
    J Infect Dis; 1980 May; 141(5):580-9. PubMed ID: 6768812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of immune responses and related patho-inflammatory reactions of a candidate inactivated EV71 vaccine in neonatal monkeys].
    Zhang XM; Zhao HL; Wang JJ; Liao Y; Na RX; Wang LC; Liu LD; Gao JH; Tang DH; Wang CZ; Li QH
    Zhonghua Yi Xue Za Zhi; 2011 Jul; 91(28):1977-81. PubMed ID: 22093894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lassa fever: implications of T-cell immunity for vaccine development.
    ter Meulen J
    J Biotechnol; 1999 Aug; 73(2-3):207-12. PubMed ID: 10486929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standardization of a plaque assay for Lassa virus.
    Tomori O; Johnson KM; Kiley MP; Elliott LH
    J Med Virol; 1987 May; 22(1):77-89. PubMed ID: 3585290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.